John Couling compensation by year
Dolby Laboratories Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $541,654 | $554,000 | $570,750 | $575,000 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $2,380,494 | $2,222,987 | $2,175,205 | $2,378,968 |
| Option awards | $761,975 | $727,949 | $740,889 | $787,598 |
| Non-equity incentive | $130,351 | $355,446 | $323,294 | $351,325 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $33,155 | $35,745 | $37,385 | $37,991 |
| Total | $3,847,629 | $3,896,127 | $3,847,523 | $4,130,882 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Dolby Laboratories, Inc. DEF 14A filed December 16, 2025, accession 0001193125-25-320032, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Dolby Laboratories, Inc. filed document, accession 0001193125-25-320032. Every figure is read from that document and cited to the page and table it appears in. Filed December 16, 2025.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 20,733 | $1,500,862 | — |
| RSU | 12,978 | $939,477 | — |
| RSU | 10,558 | $764,294 | — |
| PSU | 10,366 | $750,395 | — |
| PSU | 10,557 | $746,221 | — |
| PSU | 4,325 | $313,087 | — |
| RSU | 4,257 | $308,164 | — |
| Option | 36,446 | — | $77.91 |
| Option | 2,203 | — | $91.80 |
| Option | 17,060 | — | $87.49 |
| Option | 11,880 | — | $71.07 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Dolby Laboratories, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
32 Form 4 lines since the FY2025 proxy (filed December 16, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-01 | Sale | 10b5-1 | 6,831 | $58.72 | 167,639 |
| 2026-10-01 | Exercise or conversion derivative | 10b5-1 | 7,667 | $0.00 | 0 |
| 2026-10-01 | Sale | 10b5-1 | 836 | $59.33 | 166,803 |
| 2026-10-01 | Exercise or conversion | 10b5-1 | 7,667 | $45.50 | 174,470 |
| 2026-09-15 | Grant or award | — | 48,076 | $0.00 | 166,803 |
| 2026-09-01 | Sale | 10b5-1 | 7,667 | $61.05 | 118,727 |
| 2026-09-01 | Exercise or conversion | 10b5-1 | 7,667 | $45.50 | 126,394 |
| 2026-09-01 | Exercise or conversion derivative | 10b5-1 | 7,667 | $0.00 | 7,667 |
The 8 most recent of 32 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Dolby Laboratories discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | — | $4,732,397 | — | $4,732,397 |
| Change in control and resignation for good reason | — | $4,732,397 | — | $4,732,397 |
| Change in control, no termination | — | $4,732,397 | — | $4,732,397 |
Per the Potential Payments Upon Termination or Change in Control table in Dolby Laboratories, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Dolby Laboratories’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kevin Yeaman | President and Chief Executive Officer | $10,193,397 |
| John Couling · this page | Senior Vice President, Entertainment | $4,130,882 |
| Andy Sherman | Executive Vice President, General Counsel and Corporate Secretary | $4,044,164 |
| Shriram Revankar | Senior Vice President, Advanced Technology Group | $3,688,289 |
| Robert Park | Senior Vice President and Chief Financial Officer | $3,620,627 |
John Couling's compensation dossier, Dolby Laboratories
You have read John Couling's totals and holdings. The dossier adds each equity grant Dolby Laboratories disclosed for John Couling and Dolby Laboratories's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Dolby Laboratories compensation record
free company briefThis page is one person within Dolby Laboratories's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Dolby Laboratories proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Dolby Laboratories's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Dolby Laboratories's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order DLB
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.